Skip to main content
. 2022 Feb 22;18(1):2027714. doi: 10.1080/21645515.2022.2027714

Table 1.

Study characteristics

Study Year Country Study designa Number Sex ratio
(Male/Female)		 Age Categories of exposure Vaccine name/manufacturer RIGb Immunogenicityc Safetyc
PVRVe                      
Li14 2020 China RCT 150 0.92 10–60 NRd NR - √ √
Fan15 2019 China RCT 200 0.92 40 ± 26.7 NR Guangzhou NuoCheng NR × √
Chen16 2018 China RCT 200 1.17 2–68 I & II Guangzhou NuoCheng - × √
Peng17 2016 China RCT 869 NR >2 II NR NR × √
Peng17 2016 China RCT 941 NR >2 II NR NR × √
Peng17 2016 China RCT 881 NR >2 II NR NR × √
Bose18 2016 India RCT 60 3 5–77 II & III Rabivax-S ± √ √
Ramezankhani19 2016 Iran RCT 702 3.74 26.8 ± 13.1 II & III Verorab NR × √
Fang20 2014 China RCT 28 NR 19–60 II Liaoning ChengDa NR √ √
Wang21 2011 China RCT 200 0.63 6–67 NR Speeda NR √ ×
Wang21 2011 China RCT 50 1.27 16–78 NR Verorab NR √ ×
Liu22 2011 China RCT 30 0.88 22–57 NR SPEEDA NR √ √
Ashwathnarayana23 2009 India RCT 50 5.25 8–55 II & III Verorab ± √ √
Shu24 2007 China RCT 300 NR >2 II & III Liaoning ShengWu - × √
Shu24 2007 China RCT 300 NR >2 II & III Changchun ChangSheng - × √
Cao25 2007 China RCT 1250 0.69 2–80 I & II Liaoning ChengDa - × √
Cao25 2007 China RCT 1180 0.97 2–80 I & II Verorab - × √
Sampath26 2005 Pakistan RCT 75 NR NR II Abhayrab - √ ×
Sampath26 2005 Pakistan RCT 67 NR NR III Abhayrab - √ ×
Sampath26 2005 Pakistan RCT 88 NR NR III Abhayrab + √ ×
Huang27 2018 China P. O. 58 2.22 NR NR NR NR × √
Liu28 2012 China P. O. 398 1.17 2–67 NR Verorab - √ √
Lu29 2010 China P. O. 300 0.99 3–65 II Verorab - × √
Niu30 2019 China R. O. 5347 NR NR NR Changchun ChangSheng NR × √
PCECVf                      
Peng17 2016 China RCT 813 NR >2 II NR NR × √
Bose18 2016 India RCT 60 2.75 5–77 II & III Rabipur ± √ √
Ramezankhani19 2016 Iran RCT 747 4.7 27.4 ± 13.9 II & III Rabipur NR × √
Fang20 2014 China RCT 28 NR 19–60 II Rabipur NR √ √
Shao31 2013 China RCT 400 NR 18–59 II & III Rabipur NR √ √
Ashwathnarayana23 2009 India RCT 50 4 7–48 II & III Rabipur ± √ √
D.J. Briggs32 2000 Thailand RCT 57 0.97 5–66 II & III NR ± √ √
Benjavongkulchai33 1997 Thailand RCT 17 NR NR I & II Kaketsuken - √ √
Benjavongkulchai33 1997 Thailand RCT 21 NR NR III Kaketsuken + √ √
Benjavongkulchai33 1997 Thailand RCT 21 NR NR III Kaketsuken + √ √
Sirikun34 2018 Thailand P. O. 29 0.45 19–73 III Rabipur + √ √
Narayana35 2014 India P. O. 129 3.61 18–55 II & III Vaxirab-N ± √ √
Lu29 2010 China P. O. 300 0.95 3–65 II NuoHua - × √
HDCVg                      
Li14 2020 China RCT 150 0.86 12–60 NR NR - √ √
Fan15 2019 China RCT 200 0.56 43 ± 28.9 NR Chendu KangHua - × √
Chen16 2018 China RCT 200 1.3 2–68 I & II Kanghua - × √
Sudarshan36 2008 India RCT 29 4 15–55 II & III Rabivax ± √ √
Sudarshan36 2008 India RCT 16 4 15–55 II & III MIRV ± √ √
Sudarshan36 2008 India RCT 148 3.11 5–55 II & III Rabivax ± √ √
Benjavongkulchai33 1997 Thailand RCT 39 NR NR III NR + √ √
Yan37 2018 China P. O. 700 NR 7–60 NR Kanghua ± × √
Huang27 2018 China P. O. 53 1.79 NR NR NR NR × √
Wilde38 1995 Thailand P. O. 100 2.13 2–60 III NR ± √ √
Anderson39 1980 America P. O. 90 1.5 1–83 NR Wyeth Laboratories + √ √
Bahmanyar40 1976 Iran P. O. 45 3.1 3–90 NR Institute Merieux ± √ ×
Niu30 2019 China R. O. 464 NR NR NR Kanghua NR × √

a: RCT represents randomized controlled trial; P. O. represents reprospective observational; R. O. represents retrospective observational. b: RIG represents rabies immunoglobulin; ”-” represents no injection of RIG; ”+” represents injection of RIG; ”±” represents injection of RIG for part of the subjects. c: ”√” represents the study provide corresponding data; ”×” represents not. d: NR represent not reported. e: PVRV represents purified Vero cell vaccine. f: PCECV represents purified chick embryo cell vaccine. g: HDCV represents human diploid cell vaccine.